| 142 | |
| Summary | Gut microbes (phylum: Firmicutes) affect atezolizumab's activity. |
| Gut | |
| atezolizumab (PubChem SID: 377483935) | |
| Firmicutes (Tax ID: 1239) | |
| 32847937 | |
| affect activity | |
| Immune checkpoint inhibitors (ICI) are recently being used to treat various types of cancers. ICI blocks checkpoint proteins allowing T cells to kill the cancer cells. In a study, a correlation between the microbiome profile of patients taking (nivolumab, pembrolizumab, or atezolizumab) as monotherapy with their overall survival is conducted. it was observed that patients with a high abundance of firmicutes( Ruminococcaceae and Agathobacter) in their gut microbiome show a favorable objective response rate of more than 6 months. in addition to patients with high Ruminococcaceae abundance show overall survival rates of more than 12 months. |
Browse Drug-Microbiome Relationship
Home